Chronic hepatitis B: Update of recommendations

Authors

  • Anna S.F. Lok,

    Corresponding author
    1. Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI
    • Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362
    Search for more papers by this author
    • fax: 734-936-7392

    • A.S.F.L. serves on the advisory board of Gilead Sciences, Glaxo SmithKline, Idenix, and XTL Biopharmaceuticals, She also receives research support from Bristol-Myers Squibb, Gilead Sciences, Glaxo SmithKline, Idenix, Roche, and Schering.

  • Brian J. McMahon

    1. Viral Hepatitis Program, Alaska Native Medical Center and Arctic Investigations Program, Centers for Disease Control, Anchorage, AK
    Search for more papers by this author
    • B.J.M. has received research support grants from Glaxo SmithKline for Hepatitis A vaccine studies in the past. He currently receives a research grant from Prometheus. His spouse owns 100 shares of Glaxo SmithKline in her individual retirement account.


  • This is a US government work. There are no restrictions on its use.

  • All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material.

Ancillary